Mostrar el registro sencillo del ítem

dc.contributor.authorTorrecilla, C.
dc.contributor.authorFernández-Concha, J.
dc.contributor.authorCansino, J. R.
dc.contributor.authorMainez, J. A.
dc.contributor.authorAmón, J. H.
dc.contributor.authorCostas, S.
dc.contributor.authorAngerri, O.
dc.contributor.authorEmiliani, E.
dc.contributor.authorArrabal Martín, M. A.
dc.contributor.authorArrabal Polo, M. A.
dc.contributor.authorGarcía, A.
dc.contributor.authorReina, M. C.
dc.contributor.authorSánchez García, Juan Francisco
dc.contributor.authorBudía, A.
dc.contributor.authorPérez Fentes, Daniel Alfonso
dc.contributor.authorGrases, F.
dc.contributor.authorCosta-Bauzá, A.
dc.contributor.authorCuñé, J.
dc.date.accessioned2022-04-26T07:45:02Z
dc.date.available2022-04-26T07:45:02Z
dc.date.issued2020
dc.identifier.issn1471-2490
dc.identifier.otherhttps://www.ncbi.nlm.nih.gov/pubmed/32503502es
dc.identifier.urihttp://hdl.handle.net/20.500.11940/16561
dc.description.abstractBACKGROUND: Encrustation of ureteral double J stents is a common complication that may affect its removal. The aim of the proposed study is to evaluate the efficacy and safety of a new oral composition to prevent double J stent encrustation in indwelling times up to 8 weeks. METHODS: A double-blinded, multicenter, placebo-controlled trial was conducted with 105 patients with indwelling double J stents enrolled across 9 public hospitals in Spain. The patients were randomly assigned (1:1) into intervention (53 patients) or placebo (52 patients) groups for 3 to 8 weeks and both groups self-monitored daily their morning urine pH levels. The primary outcome of analysis was the degree of stent ends encrustation, defined by a 4-point score (0 - none; 3 - global encrustation) using macroscopic and electron microscopy analysis of crystals, after 3 to 8-w indwelling period. Score was exponentially transformed according to calcium levels. Secondary endpoints included urine pH decrease, stent removal, and incidence of adverse events. RESULTS: The intervention group benefits from a lower global encrustation rate of stent ends than placebo group (1% vs 8.2%; p < 0.018). Mean encrustation score was 85.12 (274.5) in the placebo group and 18.91 (102.27) in the intervention group (p < 0.025). Considering the secondary end points, treated patients reported greater urine pH decreases (p = 0.002). No differences in the incidence of adverse events were identified between the groups. CONCLUSIONS: Our data suggest that the use of this new oral composition is beneficial in the context of ureteral double J indwelling by decreasing mean, as well as global encrustation. TRIAL REGISTRATION: This trial was registered at www.clinicaltrials.gov under the name "Combined Use of a Medical Device and a Dietary Complement in Patient Urinary pH Control in Patients With an Implanted Double J Stent" with date 2nd November 2017, code NCT03343275, and URL.en
dc.rightsAtribución 4.0 Internacional
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.meshAdult*
dc.subject.meshMethionine*
dc.subject.meshMiddle Aged*
dc.subject.meshUreter*
dc.subject.meshCalcinosis*
dc.subject.meshCrystallization*
dc.subject.meshProsthesis Failure*
dc.subject.meshUrine*
dc.subject.meshDouble-Blind Method*
dc.subject.meshPostoperative Complications*
dc.subject.meshHydrogen-Ion Concentration*
dc.subject.meshHumans*
dc.subject.meshStents*
dc.subject.meshProspective Studies*
dc.subject.meshPhytic Acid*
dc.titleReduction of ureteral stent encrustation by modulating the urine pH and inhibiting the crystal film with a new oral composition: a multicenter, placebo controlled, double blind, randomized clinical trialen
dc.typeJournal Articlees
dc.authorsophosTorrecilla, C.;Fernández-Concha, J.;Cansino, J. R.;Mainez, J. A.;Amón, J. H.;Costas, S.;Angerri, O.;Emiliani, E.;Arrabal Martín, M. A.;Arrabal Polo, M. A.;García, A.;Reina, M. C.;Sánchez, J. F.;Budía, A.;Pérez-Fentes, D.;Grases, F.;Costa-Bauzá, A.;Cuñé, J.
dc.identifier.doi10.1186/s12894-020-00633-2
dc.identifier.pmid32503502
dc.identifier.sophos39418
dc.issue.number1es
dc.journal.titleBmc urologyes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Santiago de Compostela - Complexo Hospitalario Universitario de Santiago de Compostela::Uroloxíaes
dc.organizationServizo Galego de Saúde::Estrutura de Xestión Integrada (EOXI)::EOXI de Vigo - Complexo Hospitalario Universitario de Vigo::Uroloxíaes
dc.page.initial65es
dc.rights.accessRightsopenAccess
dc.subject.decscalcinosis*
dc.subject.decsconcentración de iones hidrógeno*
dc.subject.decsácido fítico*
dc.subject.decsorina*
dc.subject.decsfallo de prótesis*
dc.subject.decsestudios prospectivos*
dc.subject.decscristalización*
dc.subject.decsmediana edad*
dc.subject.decsuréter*
dc.subject.decsadulto*
dc.subject.decsmétodo con doble ocultación*
dc.subject.decscomplicaciones postoperatorias*
dc.subject.decsstents*
dc.subject.decshumanos*
dc.subject.decsmetionina*
dc.subject.keywordCHUSes
dc.subject.keywordCHUVIes
dc.typefidesArtículo Originales
dc.typesophosArtículo Originales
dc.volume.number20es


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución 4.0 Internacional
Excepto si se señala otra cosa, la licencia del ítem se describe como Atribución 4.0 Internacional